Recombinant human acid sphingomyelinase as an adjuvant to sorafenib treatment of experimental liver cancer.

PLoS One · 2013 · PMC3665770 · PMID 23724146

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

A trend towards better survival in the rhASM/sorafenib treatment group also was observed, although this did not reach statistical significance over sorafenib.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.